micro parts to market... faster

Merging Factors Driving the Growth of Dry Powder Inhaled Delivery

4/27/17     The search for improved routes of administration for therapeutic agents and the desire for noninvasive delivery methods for self-medication of chronic conditions have led to increased interest in pulmonary drug delivery systems. Recent developments, including ongoing research activity in powder formulations, advances in particle engineering, and novel device designs have positioned dry powder inhalation as an attractive option for the pharma and biotech industries.
Inhalers for the treatment of upper respiratory ailments, like asthma and chronic obstructive pulmonary disease, are arguably the most mission-critical drug delivery device class currently on the market. These combination products are relied upon by tens of millions of Americans and more than 300 million worldwide for the treatment of debilitating and life-threatening respiratory conditions.
As managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient-friendly and cost-effective.


The market for inhaled drugs targeting upper respiratory diseases is a maturing technology with most development activity now centering on combination drug inhalers. Oral inhalers containing two drugs that compliment the therapeutic actions of one another is one of the key factors in the DoseOne™ single dose powder inhaler (US Patent #7,832,399 B2 and #8,360,057 B2). Combination inhalers most commonly consist of an inhaled corticosteroid in combination with a bronchodilator. These products are showing significant commercial success in the two markets for which they are indicated – Asthma and COPD – both of which are forecast to grow at impressive rates for the remainder of the decade.

In the area of inhaler technology, MES has the exclusive worldwide rights to sell one of the most innovative DPIs available today, the DoseOne™ Single Dose Powder Inhaler. This 3-component inhaler is easy to use, has a low manufacturing cost and is equipped with a simple dose readiness indicator and a dose delivery indicator. If you are interested in partnering with MES on the DoseOne™ product, or you are looking to explore some of the possibilities that exist for the development of ultra precision devices for other medical applications, please email Donna Bibber at donna@microengineeringsolutions.com. For full details of DoseOne™ see www.dose-one.com.